Enlivex Therapeutics (Israel) Probability of Future Stock Price Finishing Over 375.31

ENLV Stock  ILA 455.20  2.60  0.57%   
Enlivex Therapeutics' future price is the expected price of Enlivex Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Enlivex Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Enlivex Therapeutics Backtesting, Enlivex Therapeutics Valuation, Enlivex Therapeutics Correlation, Enlivex Therapeutics Hype Analysis, Enlivex Therapeutics Volatility, Enlivex Therapeutics History as well as Enlivex Therapeutics Performance.
For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.
  
Please specify Enlivex Therapeutics' target price for which you would like Enlivex Therapeutics odds to be computed.

Enlivex Therapeutics Target Price Odds to finish over 375.31

The tendency of Enlivex Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above  375.31  in 90 days
 455.20 90 days 375.31 
roughly 96.0
Based on a normal probability distribution, the odds of Enlivex Therapeutics to stay above  375.31  in 90 days from now is roughly 96.0 (This Enlivex Therapeutics probability density function shows the probability of Enlivex Stock to fall within a particular range of prices over 90 days) . Probability of Enlivex Therapeutics price to stay between  375.31  and its current price of 455.2 at the end of the 90-day period is about 25.45 .
Assuming the 90 days trading horizon Enlivex Therapeutics has a beta of -0.0554 suggesting as returns on the benchmark increase, returns on holding Enlivex Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Enlivex Therapeutics is likely to outperform the market. Additionally Enlivex Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Enlivex Therapeutics Price Density   
       Price  

Predictive Modules for Enlivex Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enlivex Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
450.47455.20459.93
Details
Intrinsic
Valuation
LowRealHigh
393.68398.41500.72
Details
Naive
Forecast
LowNextHigh
500.85505.58510.31
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
353.51417.86482.22
Details

Enlivex Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Enlivex Therapeutics is not an exception. The market had few large corrections towards the Enlivex Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enlivex Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enlivex Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.02
β
Beta against Dow Jones-0.06
σ
Overall volatility
64.85
Ir
Information ratio -0.03

Enlivex Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enlivex Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enlivex Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Enlivex Therapeutics generated a negative expected return over the last 90 days
Enlivex Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (14.47 M) with profit before overhead, payroll, taxes, and interest of 0.
Enlivex Therapeutics has accumulated about 90.6 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Roughly 12.0% of the company shares are held by company insiders

Enlivex Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enlivex Stock often depends not only on the future outlook of the current and potential Enlivex Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enlivex Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding18.3 M
Shares Float14.3 M

Enlivex Therapeutics Technical Analysis

Enlivex Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Enlivex Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Enlivex Therapeutics. In general, you should focus on analyzing Enlivex Stock price patterns and their correlations with different microeconomic environments and drivers.

Enlivex Therapeutics Predictive Forecast Models

Enlivex Therapeutics' time-series forecasting models is one of many Enlivex Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Enlivex Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Enlivex Therapeutics

Checking the ongoing alerts about Enlivex Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Enlivex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Enlivex Therapeutics generated a negative expected return over the last 90 days
Enlivex Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (14.47 M) with profit before overhead, payroll, taxes, and interest of 0.
Enlivex Therapeutics has accumulated about 90.6 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Roughly 12.0% of the company shares are held by company insiders

Additional Information and Resources on Investing in Enlivex Stock

When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:
Check out Enlivex Therapeutics Backtesting, Enlivex Therapeutics Valuation, Enlivex Therapeutics Correlation, Enlivex Therapeutics Hype Analysis, Enlivex Therapeutics Volatility, Enlivex Therapeutics History as well as Enlivex Therapeutics Performance.
For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.